Literature DB >> 22739940

The influence of sex, gestational age, birth weight, blood transfusion, and timing of the heel prick on the pancreatitis-associated protein concentration in newborn screening for cystic fibrosis.

Annette M M Vernooij-van Langen1, J Gerard Loeber, Bert Elvers, Ralf H Triepels, Jos Roefs, Johan J Gille, Sandra Reijntjens, Edward Dompeling, Jeannette E Dankert-Roelse.   

Abstract

BACKGROUND: Pancreatitis-associated protein (PAP) is currently discussed as a marker in newborn screening (NBS) for cystic fibrosis (CF). However, it is not known if PAP concentrations are influenced by sex, gestational age, birth weight, blood transfusion or time of collection and what this would mean for NBS for CF.
METHODS: In 2008 all newborns in part of the Netherlands were screened for CF by an IRT/PAP protocol. PAP concentration was determined by the MucoPAP ELISA (DynaBio), which was modified to a Dissociation Enhanced Lanthanide Fluoroimmunoassay (DELFIA) method following a protocol of PerkinElmer.
RESULTS: In healthy newborns, the median PAP concentration was 0.5 μg/l (Interquartile range (IQR 0.3-0.8) whereas this was 3.2 μg/l (IQR 2.0-12.5) in CF infants. PAP concentrations were lower in premature infants 0.94 and 0.91 times for 25 to 31 + 6 weeks GA and 32 to 36 + 6 weeks respectively. A higher PAP concentration was observed in low-birth-weight infants (<2500 gram)(p = 0.001), per 100 gram birth weight gained the PAP concentration decreased with 0.1 %. PAP levels were higher after a blood transfusion, the 95th percentile increased from 1.3 to 3.6 μg/l leading to a higher false-positive rate. The PAP concentration increased when newborn screening was performed more than 168 hours (day 7) after birth (β = 1.63), the 95th percentile increased from 1.3-1.6 μg/l to 4.0 μg/l after 168 hours (72,874 newborns were screened).
CONCLUSION: Sex, birth weight, and gestational age lead to small differences in PAP concentrations without consequences for the screening algorithm. However, blood transfusion as well as performance of the heel prick after 168 hours (7 days) lead to clinically significant higher PAP levels and to a higher risk on a false-positive screening test result.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22739940     DOI: 10.1007/s10545-012-9498-6

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  19 in total

Review 1.  Newborn screening for cystic fibrosis: the practical implications.

Authors:  Kevin W Southern
Journal:  J R Soc Med       Date:  2004       Impact factor: 5.344

2.  Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.

Authors:  Jacques Sarles; Patrice Berthézène; Christian Le Louarn; Claude Somma; Jean-Marc Perini; Michael Catheline; Sophie Mirallié; Karine Luzet; Michael Roussey; Jean-Pierre Farriaux; Jacques Berthelot; Jean-Charles Dagorn
Journal:  J Pediatr       Date:  2005-09       Impact factor: 4.406

3.  Newborn screening for cystic fibrosis: techniques and strategies.

Authors:  Bridget Wilcken
Journal:  J Inherit Metab Dis       Date:  2007-05-12       Impact factor: 4.982

4.  A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis.

Authors:  S J Mayell; A Munck; J V Craig; I Sermet; K G Brownlee; M J Schwarz; C Castellani; K W Southern
Journal:  J Cyst Fibros       Date:  2008-10-28       Impact factor: 5.482

Review 5.  Guidelines for the performance of the sweat test for the diagnosis of cystic fibrosis.

Authors:  Anne Green; Jean Kirk
Journal:  Ann Clin Biochem       Date:  2007-01       Impact factor: 2.057

6.  An evaluation of screening for cystic fibrosis.

Authors:  B Wilcken
Journal:  Prog Clin Biol Res       Date:  1987

7.  Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population.

Authors:  Olaf Sommerburg; Martin Lindner; Martina Muckenthaler; Dirk Kohlmueller; Svenja Leible; Reinhard Feneberg; Andreas E Kulozik; Marcus A Mall; Georg F Hoffmann
Journal:  J Inherit Metab Dis       Date:  2010-08-17       Impact factor: 4.982

8.  An additional secretory protein in the rat pancreas.

Authors:  V Keim; G Rohr; H G Stöckert; F J Haberich
Journal:  Digestion       Date:  1984       Impact factor: 3.216

Review 9.  The stress response of the exocrine pancreas.

Authors:  Vuk Savković; Sebastian Gaiser; Juan L Iovanna; Hans Bödeker
Journal:  Dig Dis       Date:  2004       Impact factor: 2.404

10.  The pancreatitis-associated protein (PAP). A new candidate for neonatal screening of cystic fibrosis.

Authors:  J L Iovanna; C Férec; J Sarles; J C Dagorn
Journal:  C R Acad Sci III       Date:  1994-06
View more
  3 in total

1.  Timing of Newborn Blood Collection Alters Metabolic Disease Screening Performance.

Authors:  Gang Peng; Yishuo Tang; Tina M Cowan; Hongyu Zhao; Curt Scharfe
Journal:  Front Pediatr       Date:  2021-01-20       Impact factor: 3.418

2.  Cystic Fibrosis Newborn Screening in Austria Using PAP and the Numeric Product of PAP and IRT Concentrations as Second-Tier Parameters.

Authors:  Maximilian Zeyda; Andrea Schanzer; Pavel Basek; Vera Bauer; Ernst Eber; Helmut Ellemunter; Margit Kallinger; Josef Riedler; Christina Thir; Franz Wadlegger; Angela Zacharasiewicz; Sabine Renner
Journal:  Diagnostics (Basel)       Date:  2021-02-13

3.  Reducing False-Positive Results in Newborn Screening Using Machine Learning.

Authors:  Gang Peng; Yishuo Tang; Tina M Cowan; Gregory M Enns; Hongyu Zhao; Curt Scharfe
Journal:  Int J Neonatal Screen       Date:  2020-03-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.